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Cardiovascular disease (CVD) is a leading cause of morbidity and mortality for  
 
adults in the United States and has caused a significant amount of spending in healthcare.  
 
The guidelines issued by the National Cholesterol Education Program Adult Panel III 
 
emphasized the importance of low-density lipoprotein (LDL) with LDL reduction. Based  
 
on patient CV risk, the guidelines identified LDL as the primary target for cholesterol- 
 
lowering therapy. The guidelines also recommended the use of statins for both primary 
 
and secondary  prevention based on patient risk profile. With strong evidence of  
 
effectiveness of statins in secondary prevention, the focus was on primary prevention.  
 
Many randomized clinical trials (RCTs) conducted to evaluate the effects of statin  
 
therapy have shown that statins lower LDL-C by 19% to 47%. However, statin therapy in  
 
real-world studies has not shown the same level of LDL-C reduction as seen in RCTs. 
 
In published studies, LDL-C goal attainment is defined as whether a patient  
 
achieves LDL-C levels based on their CVD risk, after a specific follow-up time or the  
 
end of the study. However, no studies have considered LDL-C as a modifiable risk factor  
 
that changes over time. Examining the association between LDL-C goal attainment and  
 
CVD in a time-dependent manner may provide a more accurate estimation of the  
 
association between LDL-C levels as modified by statin therapy.  
 
The research question of this study is whether more consistent LDL-C goal  
 




objectives of this study are to 1) identify quarterly LDL-C goal attainment per ATP-III  
 
guidelines in primary prevention patients in the real-world setting, and 2) to evaluate the  
 
relationship between the time-dependent LDL-C goal attainment and CVD outcomes.  
 
Results from this study suggested risk reduction of CVD risk with more consistent  
 
LDL-C goal attainment, highlighting the importance of pharmacotherapy with the right  
 
intensity of medications, as well as medication adherence. The findings presented here  
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Cardiovascular disease (CVD) is a leading cause of morbidity and mortality for  
 
adults in the United States and has caused a significant amount of spending in healthcare  
 
[1]. In 2011, the hospitalization incidence rate for CVD was 2,983 events per 100,000  
 
person-years among the Medicare population, which paid roughly $16 billion for  
 
hospitalization cost associated with CVD diagnoses [2, 3]. The Framingham Heart Study  
 
(FHS) in 1998 identified risk factors for CVD including elevated low-density lipoprotein  
 
(LDL), low high-density lipoprotein (HDL), family premature history of CVD, and 
 
hypertension [4]. Among these risk factors, elevated LDL-C is a leading cause of CV  
 
events, as shown in animal laboratory models, epidemiological studies, as well as clinical  
 
trials [5]. Based on evidence found in the FHS, guidelines issued by the National  
 
Cholesterol Education Program Adult Panel III (ATP III) emphasized the importance of  
 
LDL with LDL reduction. The ATP III guidelines identified LDL as the primary target  
 
for cholesterol-lowering therapy. It recommended the use of statins for both primary and  
 
secondary prevention based on patient risk profile [5].  
 
In 2014, the American College of Cardiology and the American Heart Association  
 
(ACC/AHA) together with the National Heart, Lung, and Blood Institute updated  
 
guidelines on treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk  
 




by statin benefit group aimed at effective use of statins to reduce cardiovascular  
 
morbidity and mortality risk rather than focusing specifically on LDL reduction. These  
 
statin benefit groups include both primary and secondary prevention populations.  This  
 
change triggered much debate among physicians, pharmacists, and other healthcare  
 
practitioners [7-9].  
 
This thesis, which was developed and executed under ATP III guidelines,  
 
evaluates CV event risk, controlling for LDL goal attainments. The ATP III guidelines  
 
discussed two different clinical approaches to CVD risk management: primary and  
 
secondary prevention. A Cochrane review found significant reduction in a pooled  
 
analysis of CVD and stroke in statin therapy in primary prevention, when analyzing 14  
 
randomized clinical trials (RCTs) [10]. Several meta-analyses on RCTs also found a  
 
significant risk reduction in CVD [11-13].  These studies are discussed in greater detail in  
 
the following chapter. While prior events may be the largest predictor, we would  
 
ultimately like to prevent patients from having any CV event. Thus, this study will focus  
 
on CVD primary prevention.   
 
Many RCTs conducted to evaluate the effects of statin therapy have shown that  
 
statins lower LDL-C by 19% to 47% [14-18].  However, statin therapy in real-world  
 
studies has not shown the same level of LDL-C reduction as seen in RCTs [19]. A recent  
 
study that included 146,064 patients from a national registry found <70% patients  
 
attained the LDL-C goal [20]. Among a group of 2045 post-myocardial infarction  
 
patients with hypercholesterolemia, 43.4% who were treated with a statin failed to  
 
achieve the optimal LDL-C goal set by ATP III [21]. Suboptimal treatment was  
 





death compared with optimal treatment.  The possible explanations of the gap between 
 
RCTs and the real-world setting maybe the difference in study cohorts. RCTs have  
 
specifically defined inclusion and exclusion criteria versus nondiscriminative perspective  
 
of real-world setting. Undocumented social activity, cost, lack of motivation, non- 
 
controlled medication adherence as well as loss of information when switching healthcare  
 
providers all contributed to the less desirable LDL-C reduction seen in real-world studies.  
 
In published studies, LDL-C goal attainment is defined as whether a patient  
 
achieves LDL-C levels based on their CVD risk, after a specific follow-up time or the  
 
end of the study. However, no studies have considered LDL-C as a modifiable risk factor  
 
that changes over time. Examining the association between LDL-C goal attainment and  
 
CVD in a time-dependent manner may provide a more accurate estimation of the  
 
association between LDL-C levels as modified by statin therapy.  
 
The research question of this study is whether more consistent LDL-C goal  
 
attainment reduces the incidence of CV events in primary prevention patients. The  
 
objectives of this study are to 1) identify quarterly LDL-C goal attainment per ATP-III  
 
guidelines in primary prevention patients in the real-world setting, and 2) to evaluate the  
 
relationship between the time-dependent LDL-C goal attainment and CVD outcomes. 
 
This study has found a positive association between more severe ATP III risk and  
 
less LDL-C goal attainment in the primary prevention real-world setting. It also found a  
 
significant association between the risk of CV events and LDL-C goal attainment;  
 
notably, that failure to attain or maintain LDL-C goal at any time during the follow-up  
 
period increased the likelihood of a CV event occurrence by 30%.  
 





LDL-C goal attainment, highlighting the importance of pharmacotherapy with the right  
 
intensity of medications, as well as medication adherence. The findings presented here  
 
add to the knowledge of the association between LDL-C goal attainment and CV event  
 
risk reduction. While guidelines are now less specific about specific LDL-C goals, this  
 
study nonetheless is consistent with the rationale for treating patients at risk for CVD  
 








2.1 Background  
 
Cardiovascular disease (CVD) is a set of diseases and disorders that involves the  
 
heart and blood vessels. CVD includes ten categories, with the five most common  
 
diseases being coronary heart disease (CHD), cerebrovascular disease, peripheral heart  
 
disease, rheumatic heart disease, and heart failure. According to the report, an estimated  
 
17 million American adults had CVD in 2008, which was 7% of the total U.S. adult  
 
population [1]. In 2011, the hospitalization incidence rate for CVD was 2,983 events per  
 
100,000 person-years among the Medicare population, which paid roughly $16 billion for  
 
the hospitalization cost associated with CVD diagnoses [3] .  
 
There are many risk factors associated with CVD, including family history,  
 
ethnicity, age, tobacco exposure, high blood pressure, high cholesterol, obesity, physical  
 
inactivity, and diabetes. However, Low-density lipoprotein (LDL-C), a modifiable risk  
 
factor, was the main concern [22]. LDL-C is among the major groups of lipoproteins.  
 
It contains a single apolipoprotein B-100 molecule that keeps LDL-C soluble in blood,  
 
which allows it to transport cholesterol [23].   
 
A range of observational and RCT studies published over several decades based  
 
on animal, pathological, clinical, and genetics have established a causal role of elevated 
 




guidelines identified elevated LDL-C as a primary target for CVD risk reduction. It also  
 
proposes LDL-C <100 mg/dL as the optimal level, 100-129 mg/dL as near optimal, 130- 
 
159 mg/dL as borderline high, 160-189 mg/dL as high, and ≥190 mg/dL as very high [5].  
 
In addition to LDL-C, ATP III also defined risk factors such as low high-density  
 
lipoprotein (HDL) level (<40 mg/dL), hypertension (blood pressure≥140/90 mmHg),  
 
cigarette smoking, family history of premature CVD, and age (men≥45 years, women≥55  
 
years) for developing CV events [5].  
 
 
2.2 Approach for Lipid Control: Statin Therapy 
 
Clinically, therapeutic lifestyle change (TLC) and drug therapy have been adopted  
 
to reduce risks for developing CVD [4]. According to ATP III guidelines, physicians  
 
should consider drug therapy when patients 1) have one ATP III risk factor with LDL- 
 
C >190 mg/dL; or 2) have two or more ATP III risk factors and <20% 10-year risk with  
 
LDL-C >130 mg/dL; or 3) have previous CV events or CVD equivalents with LDL-C >  
 
100 mg/dL.  
 
When initiating drug therapy, available medications include: HMG-CoA  
 
reductase inhibitors (statins), bile acid sequestrants, nicotinic acid, and fibric acids. ATP  
 
III guidelines recommend that statins be considered the first-line for cholesterol-lowering  
 




In 2014, American College of Cardiology and American Heart Association  
 
together with National Heart, Lung, and Blood Institute published new guideline [6].  
 
Although it continued to stress the significance of initiating cholesterol-lowering therapy  
 




which is a notable departure from previous guidelines. However, this research was  
 
conducted during a timeframe in which providers would have been following ATP III  
 
guidelines and based on the notion that even if LDL-C was not necessarily the strongest  
 
predictor, it is still relevant to CVD outcomes.  
 
 
2.3 Approach for Events Prevention: Primary Prevention 
 
While prior events may be the largest predictor, we would ultimately like to  
 
prevent a patient from having any CV event. In clinical practice, primary prevention is to  
 
prevent patient from have a CV event. This practice denotes efforts to prevent or delay  
 
occurrence of disease which would result in a CV event by modifying risk factors. Many  
 
RCTs have focused on CVD primary prevention through lipid lowering including: the  
 
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese  
 
(MEGA) [17], the Atorvastatin Study for Prevention of Coronary Heart Disease  
 
Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) [14], the Justification for  
 
the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin  
 
(JUPITER) [26], the Collaborative Atorvastatin Diabetes Study (CARDS) [15], and the  
 
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS) [27].  
 
 
2.3.1 RCTs on Lipid Control 
 
According to results from these trials, significant LDL-C absolute reduction was  
 
observed with statin therapy, ranging from 18.5% to 47.2% [14, 17, 26, 27]. Significant  
 
reduction in HDL, total cholesterol (TC), and triglycerides (TG) was also noted  
 







2.3.2 RCTs on Primary Endpoint 
 
In addition to lipid control, the five RCTs mentioned above also reported CV  
 
event outcomes. The results revealed that statin therapy significantly reduced the risk of a  
 
major CV event when considered as a composite primary endpoint. Strong evidence was  
 
also seen in statin treatments in individual studies, with statistically significant reductions  
 
in major CV events ranging from 33% to 44% [14-17, 27].  
 
Specific outcomes such as MI, coronary revascularization, angina, and stroke  
 
were also reported as individual components of the composite primary endpoints.  
 
Although results differed slightly in particular outcomes, beneficial effects of statins in  
 
terms of CVD risk reductions were observed across all individual outcomes in the  
 
majority of RCTs. For example, in MI, the hazard ratios were 0.52 [95% CI: 0.29-0.94],  
 





2.3.3 Cochrane Review  
 
In a recent Cochrane systemic review, researchers included 14 trials (covering  
 
MEGA, AFCAPS, ASPEN, and CARDS), which recruited 34,272 participants and  
 
observed outcomes ranging from 1-5.3 years, amounting to approximately 113,000  
 
patient-years [28].  
 
The review found no evidence of reduction in total mortality (all-cause mortality),  
 
fatal CV events, or non-fatal CV events. However, statistically significant effects were  
 
observed in a pooled analysis of fatal or non-fatal stroke events and revascularization.  
 
When combining CVD and stroke, a significant reduction was also maintained with a  
 





were parallel to results seen in individual trials [28]. 
 
 
2.3.4 Meta Analysis 
 
 Numerous meta-analyses have been published, examining the effects of statins  
 
seen in a variety of RCTs. To date, five studies focused exclusively on primary  
 
prevention [11-13, 29, 30]. All studies detected around 30% reduction in major coronary 
 
heart disease. In major cerebrovascular disease, four of the five studies showed more than  
 
20% reduction that was significant [10-12, 30]  while one showed 14% reduction that  
 
was not significant [13]. Three studies found no effect of statin therapy in reducing all- 
 
cause mortality events [11-13] , while two observed 16% and 12% significant reduction  
 
in all-cause mortality [30] . There was no effect of statin therapy in reducing CVD fatal  
 
events from the Cochrane Review and Brugts et al. while Choudhry et al. detected 23%  
 
significant reduction in CVD mortality [10, 30]] 
 
 
2.3.5 Gap between RCTs and the Real-world Setting 
 
The five aforementioned primary prevention RCTs used restrictive inclusion and  
 
exclusion criteria that may affect the external validity of these trials. JUPITER and  
 
AFCAPS excluded patients with type 2 diabetes [26, 27]. JUPITER also excluded  
 
patients with blood pressure higher than 190/100 mmHg, while AFCAPS excluded  
 
patients with ‘uncontrolled hypertension’ and those whose weight was 50% more than 
 
desired limit for the height. MEGA excluded poorly controlled hypertension and diabetes  
 
patients [31] . ASPEN excluded patients with HbA1C>10%, blood pressure higher than  
 
160/100 mmHg, and patients with BMI >35 kg/m2. [14] Therefore, the external validity  
 
of clinical trials was reduced due to the exclusion of patients with high blood pressure,  
 









CVD is prevalent in US adult population, and benefits of statin therapy in LDL-C  
 
lowering toward primary CVD risk reductions are seen in clinical trials. LDL-C goal  
 
attainment reported as LDL-C changes from baseline to either an intermediate follow-up  
 
or end of pharmacotherapy program is an important factor for physicians. Physicians  
 
could benefit from an observational study that focuses on the impact of CVD by LDL-C  
 
goal attainment over time. These data are, however, missing in current literature.  
 
Therefore, this study is designed to answer the question of how LDL-C goal  
 





RESEARCH GOAL AND OBJECTIVES 
 
 
The goal of this study is to evaluate the relationship between statin therapy for  
 
primary prevention and CVD outcomes in the real-world setting. To accomplish this goal,  
 
the following study objectives were addressed: 
 
• Identify and describe a cohort of patients with the first statin prescription  
 
order, defined as the index date, and no previous CVD prior to the index date  
 
treated in the real-world setting  
 
• Identify and describe the incidence of CV events with stratification by  
 
proportion of time at the LDL-C goal 
 
• Evaluate the relationship between LDL-C goal attainment, defined using  
 
a threshold from the ATP III guideline, as a time-dependent variable using a  
 
Cox’s proportional hazard model. 
 
The rational of this study is as follows. When a patient is prescribed statins, it is  
 
expected to lower the patient’s LDL-C. There are reasons that a patient may have  
 
suboptimal LDL-C response and failure to attain a goal with treatment, such as  
 
comorbidities including hypertension, diabetes, and obesity [32]. It has been well  
 
established that suboptimal LDL-C response will increase risk of CVD [8]. What remains 
 
 unknown in primary prevention is how the incidence of CV events changes with  
 




world study that focuses on the relationship between LDL-C response to statin therapy as  
 
measured by goal attainment and CV event outcomes in primary prevention could  
 
provide information on the difference in incidence of CV events by LDL-C goal  
 
attainment. With this information, physicians could assess patient CVD risk given the  
 
patient’s response to statin therapy relative to LDL goals.  Physicians could also counsel  
 
patients on the implications of suboptimal LDL-C goal attainment when addressing  
 
medication compliance issues, especially when patients do not fully understand their risk  
 
for a CV event in primary prevention. 
 
In addition, data on the relationship between CVD risk and LDL-C goal  
 
attainment over time in the real-world setting are also lacking, and more informative than  
 
only considering time-static or average LDL-C level. A patient’s LDL-C levels change  
 
over time. Rather than computing an average of all available LDL-C records over a  
 
defined follow-up period, considering all LDL-C values over a follow-up period would  
 
help assess the association between time at or above the LDL-C goal and CVD risk. This  
 
could provide essential information to physicians about the importance of consistently  
 
keeping LDL-C at or below a goal over time, or conversely, the risk associated with  
 









4.1 Study Design 
 
A retrospective cohort study for the period from January 1996 to December 2010  
 
among patients in an Electronic Medical Record (EMR) database without prior history of  
 
cardiovascular disease with a first-time statin prescription order was conducted.  
 
 
4.2 Study Timeline 
 
Based on General Electric EMR (GE EMR) data, patients who met the inclusion  
 
criteria from January 1996 to December 2010 were identified. The date of the first statin  
 
prescription order was defined as the index date. Patients were followed for a year and  
 
one extra month prior to the index date to confirm they were treatment naïve and that  
 
they were primary prevention patients, and for 900 days post index date to assess LDL-C  
 
and outcomes. The reason for this 395 days is that the EMR database only captures  
 
prescriptions, but not dispensing as seen in the claims database. Situations might arise  
 
when patients refill early in December and wait until the end of January to see the  
 
physician again. The phantom that the patient was not taking any medications in the  
 
exclusion or inclusion list could be revealed by requiring one extra month for treatment  
 
naïve confirmation.  
 





the study without a CV event (December 2010), or 3) the end of the patient’s EMR  
 
activity. A CV event was defined as an ischemic heart disease event including MI [ICD-9  
 





4.3 Data Source 
 
This proposed study used data from the GE Centricity EMR research database  
 
(GE Healthcare, Waukesha, WI). The GE EMR, a de-identified, HIPAA-compliant  
 
database, was comprised of longitudinal patient data and includes, but was not limited to,  
 
demographic information, vital signs, laboratory orders and results, medication list  
 
entries and prescribed medications, and diagnoses or problems. Medical record data were  
 
submitted by over 100 physician practice sites located in 42 states who participate in the  
 
Medical Quality Information Consortium (MQIC). Consortium members represent a  
 
variety of practice types including solo practices, group practice, community clinics,  
 
academic medical centers, and large integrated delivery networks, all representing  
 
ambulatory care settings. Currently, the EMR includes data on over 15 million patients.  
 
 
4.4 Study Population 
 
To be eligible for study inclusion, patients need to be at least 18 years old,  
 
initiated on statin therapy that includes atorvastatin, fluvastatin, lovastatin, pravastatin,  
 
rosuvastatin, simvastatin, or pitavastatin (Appendix A). The date of the first statin  
 
prescription order was defined as the index date. To help establish the intention for  
 
patients to stay on statin therapy, another statin prescription must have been documented  
 
in the EMR from 30-days to 365-days post index date.  
 




including statins, bile acid sequestrants, fibrin, niacin, or ezetimibe per prescription order  
 
or medication list entries in this period were excluded.  
 
Patients were excluded if they had a previous diagnosis of ischemic heart disease  
 
[ICD-9 410-414] (including acute myocardial infarction, other acute and sub-acute forms  
 
of ischemic heart disease, old myocardial infarction, angina pectoris, and others forms of  
 
chronic ischemic heart disease), cerebrovascular disease [ICD-9 430-438] (including  
 
subarachnoid hemorrhage, intracerebral hemorrhage, other and unspecified intracranial  
 
hemorrhage, occlusion and stenosis of precerebral arteries, occlusion of cerebral arteries,  
 
transient cerebral ischemia, acute but ill-defined cerebrovascular disease, other and ill- 
 
defined cerebrovascular disease, and late effects of cerebrovascular disease), or  
 
peripheral vascular disease [ICD-9 443]. In addition, patients with the following  
 
diagnosis throughout the study time were excluded: hepatic dysfunction [aspartate or  
 
alanine aminotransferase levels 3 times the upper limit of normal (aspartate: female 6-34  
 
U/L, male 8-40 U/L; alanine: 5-60 U/L)], and rhabdomyolysis [ICD-9 728.88].  
 
 
4.5 Variable Measurement 
 
4.5.1 Primary Independent Variable 
 
The primary independent variable was LDL-C goal attainment treated as a time- 
 
dependent variable. To identify goal attainment, all documented LDL-C levels during the  
 
900-day follow-up period were captured and were used to estimate LDL-C levels at  
 
quarterly intervals.  Quarter LDL-C goal attainments were evaluated against ATP III  
 
guidelines with a binary result: At-Goal or Not-At-Goal based on patient’s risk profile.  
 
For quarters without LCL-C measures, the missing observations were filled using the last  
 




Those whose LDL-C levels were at goal for 80-100% of the quarterly readings  
 
during their follow-up period were assigned to Goal I, those whose LDL-C levels were at  
 
goal for 79-50% of the period were assigned to Goal II, and those whose LDL-C levels  
 
were at goal for <50% of the period were assigned to Goal III. The risk factors include  
 
HDL <40 mg/dL, blood pressure ≥140/90 mmHg, and men ≥45 years or women ≥55  
 
years old. If a patient has 0-1 risk factor, LDL-C ≤160 mg/dL is the optimal level; if a  
 
patient has 2+ risk factors, LDL ≤130 mg/dL is the optimal level and ≤100 mg/dL for  
 
a patient with CHD Equivalent.  
 
 
4.5.2 Outcomes Measurement 
 
The primary outcome of interest in this study was the occurrence of composite  
 
endpoint of MI [ICD-9 410-414], Angina [ICD-9 413-414]), or cerebrovascular disease  
 
event [ICD-9 430-438] occurring from the index date to the end of the study period. The  
 





4.5.3 Other Independent Variables 
 
Other independent variables were identified to describe the patient cohort, and to  
 
control for characteristics that might influence outcomes or otherwise introduce bias to  
 
the findings as described below.  
 
 
4.5.3.1 Baseline Characteristics Description  
 
Baseline characteristics included age as of index date (continuous; and 19-44, 45- 
 
54, 55-64, 65-74, 75+), sex, race (White, Black, Hispanic, other, unknown), region  
 




4.5.3.2 Clinical Characteristics Description  
 
Clinical characteristics were captured from 365-day prior to 90-day post index 
  
date for laboratory/biometric values based on ICD-9 codes in Appendix A. 
 
The clinical characteristics included HbA1C (continuous & < 7.0/≥7.0%/not  
 
available), BMI (continuous & <25.0, 25.0-29.9, 30.0-34.9, 35.0-39.9, ≥40 kg/m2/not  
 
available), weight (continuous/not available), SBP (continuous &<130/≥130 mmHg /not  
 
available), DBP (continuous & <80/≥80 mmHg /not available), lipid values (LDL-C  
 
[continuous & ≥100/<100 mg/dL/not available], HDL-C [continuous & ≥40/<40  
 
mg/dL/not available], TC [continuous & ≥200/<200 mg/dL/not available] and TG  
 
[continuous & ≥150/<150 mg/dL/not available]), ATP III risk factors, and comorbidities  
 
(hypertension). Baseline LDL-C was defined as the closet LDL-C value to the index date.  
 
Patients were required to have at least one baseline LDL-C and two follow-up readings.  
 
One of the follow-up LDL-C readings must have been recorded at the 0-180 day period  
 
and another at the 181-900 day period to ensure patients were actively monitored. 
 
 
4.5.3.3 Additional Drug Treatment Description  
 
Since additional antihyperlipidemia and antihypertensive drug treatment may  
 
affect LDL-C, it was imperative to stratify study population by additional drug treatments.  
 
The prescription orders of antihyperlipidemia agents, including bile acid sequestrants,  
 
fibric acid derivatives, nicotinic acid derivatives, and combinations of above drugs, as  
 
well as antihypertensive agents, such as angiotensin-converting enzyme (ACE) inhibitors,  
 
α-blockers, angiotensin ii receptor,  β-blockers, calcium channel blockers, aldosterone  
 
receptor antagonists, thiazides, vasodilators, and combinations of the above drugs, were  
 




4.6 Statistical Analysis 
 
Descriptive statistics were used to describe baseline demographic and clinical  
 
characteristics. The independent t-test and χ2 test were used to detect the differences in all  
 
baseline and clinical characteristics for continuous and categorical variables, respectively,  
 
with stratification of number of ATP III risk factors. Tukey’s honest significance  
 




The incidences of the composite endpoints were identified from 90-day to 900- 
 
day post index date. The incidence was reported as events per 100 person-years.  
 
Individual endpoints of MI, angina, and cerebrovascular disease were also reported. 
 
A survival analysis using the discrete time logistic model was performed to  
 
estimate the treatment effects of independent variables. LDL-C goal attainment was  
 
included as a time-dependent exposure variable. In this model, time was treated as non- 
 
continuous. Each patient would have observations starting from the index date until 
 
censorship or event occurred, thus creating a series of monthly observations by every  
 
subject. Therefore, it was necessary to treat each patient as a cluster in order to obtain the  
 
robust standard errors. In addition to the time-dependent LDL goal attainment variable,  
 
the model also controlled for baseline demographic and clinical characteristics as  
 
covariates. An odds ratio estimate was interpreted as the odds of experiencing a CV event  
 
from one quarter to the next with having attained LDL-C goal as compared to not, while  
 
holding all other covariates constant. Finally, model diagnostics were performed with the  
 
Deviance and Pearson statistics and Hosmer-and-Lemeshow Goodness-of-Fit tests. 
 





The protocol for this study was presented to the University of Utah Institutional Review  
 








5.1 Baseline Characteristics 
 
Between January 1996 and December 2010, a total of 954,022 patients with two  
 
statin prescriptions were identified in the GE Centricity© Electronic Medical Record  
 
research database. Of these, 142,459 had no previous history of CVD from 395 days prior  
 
to and 900 days post index date activity. After excluding those with less than one LDL-C  
 
record during 0-180 days and 181-900 days post index date from the total sampling,  
 
52,126 patients were included in the final study cohort (Figure 1). 
 
 
5.1.1 LDL-C Goal Attainment 
 
Of the total study population, 31,502 (60.4%) had LDL-C goal attained for 80- 
 
100% of the follow-up period (Goal I, LDL-C levels were at goal for 80~100% of the  
 
quarterly readings during their follow-up period), 12,140 (23.3%) for 79-50% of the  
 
period (Goal II, LDL-C levels were at goal for 79-50% of the period), and 8,478 (16.3%)  
 
for <50% of the period (Goal III, LDL-C levels were at goal for <50% of the period).  
 
When stratifying the cohort by risk-specific LDL-C goal attainment, in the group  
 
with 0-1 ATP III risk factor, there were more patients who had the most time at goal  
 
(Goal I, 52.0%) than those who had the least time at goal (Goal III, 12.6%); in the group  
 





patients. Patients with higher percent of goal attainment time tended to be younger female  
 
Caucasians, living in the northeastern United States (hereafter referred to as ‘the  
 
Northeast’) and insured by commercial plans. There were statistically significant  
 





5.1.2 Baseline Demographic Characteristics 
 
Mean (standard deviation [SD]) age of the population was 57.0 (±11.2) years;  
 
over half of the cohort 30,054 (57.7%) were women. The largest proportion of patients  
 
were between the ages of 55 and 64 years (29.1%), Caucasians (38.3%), living in the  
 
southeastern United States (hereafter referred to as ‘the South’) (34.5%), and insured  
 
(36.6%). The baseline characteristics are shown in Table 2. 
 
 
5.1.3 Baseline Clinical Characteristics 
 
There were statistically significant differences in mean values among all baseline  
 
clinical characteristics when comparing stepwise among risk-specific LDL-C goal  
 
attainment groups (Table 2). 
 
 
5.1.3.1 Baseline Lipid 
 
Mean baseline LDL-C was 154.6 (±35.9) mg/dL and it ranged from 150 mg/dL  
 
for the Goal I to 166 mg/dL for the Goal III (P<0.001). Baseline LDL-C values were  
 
significantly associated with greater goal attainment. The highest proportion of Goal I  
 
patients (33.5%) had baseline LDL-C 130-159 mg/dL, the highest proportion of Goal II  
 
and Goal III patients (33.0%, 32.4%) had baseline LDL-C 160-189 mg/dL (P<0.001).  
 





Figure 2.  
 
 
5.1.3.2 Baseline HDL-C, TC, and TG 
 
Mean baseline HDL-C was 50.9 (±13.6) mg/dL. Mean baseline TC was 221.3  
 
(±36.9) mg/dL. Mean baseline TG was 158.0 (±81.6) mg/dL, noting that 44% of the  
 
patients did not have TG records.  
 
 
5.1.3.3 Baseline HbA1C and Type 2 Diabetes Mellitus 
 
Mean baseline HbA1C, when documented (n=16,096, 30.9%), was 7.0 (±1.5) %  
 
with a range from 5.8 (±0.5) % to 7.4 (±1.5) %.  Prevalence of baseline type 2 diabetes  
 
mellitus differed by LDL-C goal groups (P<0.001), with 14.1% of patient having diabetes  
 
in Goal I, 33.3% in Goal II, versus 54.1% in Goal III. 
 
 
5.1.3.4 Baseline BMI 
 
Mean BMI was 30.8 (±6.7) kg/m2, 64.9% were overweight (BMI≥ 25.0 kg/m2),  
 





5.1.3.5 Baseline Hypertension 
 
There were 27,563 (52.9%) patients with hypertension at baseline indicated by  
 
blood pressure, diagnosis of hypertension, or treated with at least one antihypertensive  
 
agent. The mean systolic blood pressure (SBP), when documented (n=50,804, 97.5%),  
 
was 130.9 (±13.5) mmHg and the mean diastolic blood pressure (DBP) was 78.8 (±7.8)  
 
mmHg. Prevalence of hypertension varied by LDL-C goal groups (P<0.001), with 41.9%  
 






5.1.4 Pharmacotherapy Characteristics 
 
About 2% of the patients were treated with additional antihyperlipidemia  
 
medications. Of these, the top 2 classes were prescribed intestinal cholesterol absorption  
 
inhibitors (n=344, 35.5%) and fibric acid derivatives (n=305, 31.5%). About 88% of 
 
patients were treated with antihypertensive medications. Of these, 11,839 (25.8%)  
 
patients were prescribed ACE inhibitors, followed by β-blockers (n=8,749, 19.1%). There  
 
were relatively similar numbers of patients prescribed thiazides (n=6,805, 14.9%),  
 
combined antihypertensive treatments (6,468, 14.2%), and calcium channel blockers  
 





5.2.1 Event Rates 
 
In total, 2,019 composite CV events occurred among 52,126 patients during a  
 
median of 2.5 years (30 months) follow-up period. The overall incidence rate was 1.61 
 
composite events per 100 person-years, ranging from 1.50 for Goal I patients, 1.72 for  
 
Goal II patients, to 1.88 for Goal III events per 100 person-years (Table 3). 
 
When considering CV events by type, there were 424 MI events, 306 new cases  
 
of Angina and 1,289 Cerebrovascular events. The incidence rate ranged from  
 
0.309 cases per 100 person-years of Goal I in MI to 1.15 cases per 100 person-years of  
 
Goal III in Cerebrovascular events. 
 
The Kaplan-Meier curve was plotted by LDL-C goal group shown in Figure 3.  
 
There were statistically significant differences in survival probability of composite CV  
 
events among LDL-C goal attainment group (p<0.001). Compared to Goal III patients,  
 





5.2.2 Survival Analysis: Discrete Time Logistic Model 
 
The result from the discrete time logistic model with LDL-C goal attainment as  
 
the time-dependent exposure was shown in Table 4 and Figure 5. The odds of  
 
experiencing composite CV events were 2.6 times for a failure at LDL-C goal in a quarter  
 
as compared to goal attainment at the same time (OR=2.6, 95% CI: [2.0-3.1], p<0.001),  
 
after adjusting for demographic characteristics including age, gender, race, region,  
 




When comparing patients with ≤1 ATP III risk factor, those with ≥2 ATP III risk  
 
factors had a higher risk of experiencing CV events (OR=1.9, 95% CI: [1.7-2.2],  
 
p<0.0001), and those with ATP III equivalency risk factors had the highest CVD risk  
 
level (OR=3.0, 95% CI:[2.5-3.5], p<0.0001). 
 
Age was associated with CVD risk. The odds ratio was 2.7 (95% CI: [2.4-3.1],  
 
p<0.0001) for those ≥ 65 years old vs. < 65 years old. 
 
Compared to males, female patients had 1.1 (95% CI: [1.0-1.2], p=0.1) times  
 
greater odds of experiencing a CV event, although this was not statistically significant.  
 
African American patients had 1.1 (95% CI: [0.8-1.4], p=0.6) times greater odds of  
 
experiencing a CV event than Caucasian patients, although race was not a statistically  
 
significant predictor of outcomes.  Compared to patients from the Northeast, the odds of  
 
experiencing CV events for patients residing in the South and Midwest were 1.2 (95%  
 
CI:[1.1-1.4], p=0.006) and 1.2 (95% CI:[1.0-1.4], p=0.0027) times higher, respectively.  
 
Patients covered by Medicare had 1.4 times higher odds of a CV event than those covered  
 






Comorbid conditions were associated with CVD risks. Hypertension was  
 







Table 1  
 




Number of Patients (Percentage, %) 
No. of Patients 
Cumulative 
Percentage, %* 0~1 2+ 
CVD/CVD 
Equivalency 
0% 4,601 (58.74) 10,540 (37.76) 4,601 (16.48) 31,537 38.64 
<10% 1,769 (8.71) 2,554 (9.15) 1,769 (6.33) 6,754 46.92 
10-20% 2,579 (8.86) 3,315 (11.87) 2,579 (9.24) 8,367 57.17 
20-30% 2,263 (6.36) 2,488 (8.91) 2,263 (8.10) 6,527 65.17 
30-40% 2,281 (5.25) 2,260 (8.09) 2,281 (8.17) 6,007 72.53 
40-50% 2,157 (3.61) 1,870 (6.70) 2,157 (7.72) 5,037 78.7 
50-60% 2,039 (2.43) 1,544 (5.53) 2,039 (7.30) 4,264 83.93 
60-70% 1,820 (2.18) 1,217 (4.36) 1,820 (6.52) 3,648 88.4 
70-80% 1,517 (1.56) 1,051 (3.76) 1,517 (5.43) 3,005 92.08 
80-90% 1,428 (1.13) 838 (3.00) 1,428 (5.11) 2,583 95.25 
90-99.9% 588 (0.36) 233 (0.83) 588 (2.10) 924 96.38 
100% 1,943 (0.74) 803 (2.87) 1,943 (6.96) 2,955 100 
____________________ 
* The cumulative percentage values might not add up from left, due to round up
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Table 2  
 
Characteristics of the Patients by LDL-C Goal Attainment 
 








Risk Factor     
0~1 16,389 (52.0) 3,397 (28.0) 1,072 (12.6) <0.001 
2+ 10,529 (33.4) 4,600 (37.9) 2,687 (31.7)  
CHD/CHD Equivalent 4,584 (14.6) 4,143 (34.1) 4,719 (55.7)  
Age   Mean (SD), years 57 (11) 57 (11) 56 (11)  
>65 8,697 (27.6) 3,133 (25.8) 2,120 (25.0) <0.001 
<=65 22,805 (72.4) 9,007 (74.2) 6,358 (75.0)  
Sex     
Female 13,511 (42.9) 5,081 (41.9) 3,479 (41.0) 0.0041 
Male 17,991 (57.1) 7,059 (58.1) 4,999 (59.0)  
Race     
Caucasian 12,338 (39.2) 4,595 (37.9) 3,024 (35.7) <0.001 
African American 1,031 (3.3) 621 (5.1) 696 (8.2)  
Hispanic 360 (1.1) 304 (2.5) 258 (3.0)  
Other 475 (1.5) 268 (2.2) 161 (1.9)  
Unknown 17,298 (54.9) 6,352 (52.3) 4,339 (51.2)  
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Region     
Northeast 9,554 (30.3) 3,998 (32.9) 2,731 (32.2) <0.001 
South 9,841 (31.2) 3,806 (31.4) 2,753 (32.5)  
Midwest 6,904 (21.9) 2,296 (18.9) 1,526 (18.0)  
West 5,150 (16.3) 2,017 (16.6) 1,447 (17.1)  
Unknown 53 (0.2) 23 (0.2) 21 (0.2)  
Insurance     
Commercial 11,643 (37.0) 4,416 (36.4) 3,002 (35.4) <0.001 
Medicare 9,122 (29.0) 3,431 (28.3) 2,363 (27.9)  
Medicaid 160 (0.5) 82 (0.7) 89 (1.0)  
Other 162 (0.5) 85 (0.7) 99 (1.2)  
Unknown 10,415 (33.1) 4,126 (34.0) 2,925 (34.5)  
BMI,  Mean (SD), kg/m2 30.27(6.4) 31.17(6.7) 32.26(7.2) <0.001 
<25 4,634 (14.7) 1,431 (11.8) 787 (9.3) <0.001 
25-29.9 9,274 (29.4) 3,357 (27.7) 2,067 (24.4)  
30-34.9 6,067 (19.3) 2,531 (20.8) 1,827 (21.5)  
35-39.9 2,691 (8.5) 1,257 (10.4) 981 (11.6)  
40+ 1,941 (6.2) 960 (7.9) 871 (10.3)  
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BMI,  Mean (SD), kg/m2     
Unknown 6,895 (21.9) 2,604 (21.4) 1,945 (22.9)  
Baseline LDL-C, mg/dL 150 (35) 159 (35) 166 (36) <0.001 
<100 2,858 (9.1) 603 (5.0) 241 (2.8) <0.001 
100-129 5,178 (16.4) 1,682 (13.9) 931 (11.0)  
130-159 10,545 (33.5) 3,644 (30.0) 2,507 (29.6)  
160-189 9,507 (30.2) 4,005 (33.0) 2,751 (32.4)  
>190 3,414 (10.8) 2,206 (18.2) 2,048 (24.2)  
Diabetes Mellitus     
Diabetic 4,438 (14.1) 4,037 (33.3) 4,585 (54.1) <0.001 
Hypertension     
Hypertensive 13,189 (41.9) 6,818 (56.2) 5,252 (61.9) <0.001 
SBP     
Mean (SD) 129.76 (13) 131.72 (13) 133.59 (14) <0.001 
DBP     
Mean (SD) 78.31 (7.8) 79.18 (7.8) 79.98 (7.9) <0.001 
HDL     
Mean (SD) 51.85 (14) 50.10 (13) 48.78 (13) <0.001 
____________________ 
* Goal I: 80~100% of the follow-up period; Goal II: 79-50% of the period; Goal III: <50% of the period. 
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Table 3  
 
Number of Events and Incidence Rate of CV Events by LDL-C Goal Attainment* 
 
____________________ 
* events per 100 person years 
Goal Group N Person Years Composite  MI Angina Cerebrovascular 
Goal I 1,136 75,936 1.496 
Case 232 142 762 
Incidence Rate 0.309 0.189 1.008 
Goal II 501 29,179 1.717 
Case 114 92 295 
Incidence Rate 0.396 0.319 1.016 
Goal III 382 20,287 1.883 
Case 78 72 232 
Incidence Rate 0.389 0.359 1.149 
Total 2,019 12,540 1.610 
Case 424 306 1,289 





Results of Discrete Time Logistic Model 
 
Parameters Odds Ratio 95% Confidence Interval P Value 
LDL-C, time-dependent¶     
At-Goal vs. Not-At-Goal 2.606 1.954 3.058 <.0001 
No. of ATP III Risk Factors     
2~3 vs. 0~1 1.917 1.702 2.159 <.0001 
CVD/CVD Equivalent vs. 0~1 2.993 2.543 3.523 <.0001 
Age, years     
>65 vs. <=65 2.721 2.394 3.093 <.0001 
Female vs. Male 1.089 0.977 1.214 0.1125 
Race     
African American vs. Caucasian 1.061 0.823 1.366 0.6486 
Unknown vs. Caucasian 1.159 1.033 1.301 0.0121 
Region     
South vs. Northeast  1.197 1.053 1.360 0.0060 
Midwest vs. Northeast 1.189 1.020 1.386 0.0027 
Insurance     
Commercial vs. Medicare 1.443 1.226 1.698 <.0001 
Hypertension     
Yes vs. No 1.338 1.182 1.516 <.0001 
____________________ 
¶ The LDL-C was the time-dependent variable. Patients’ LDL-C was measured quarterly, the status of being at-goal or not-at-
goal was determined according to ATP-III guidelines. 
 
* P-value was calculated using Tuskey HSD test, to compare differences among categories within each characteristics group; 





Figure 1 Flow Chart of Study Population Selection 
No prior anti-hyperlipidemic medication prescription 
 
N=159,640 
First prescription for statin (index date) 
 
N=1,686,205 
Second prescription for statin, 
30-day to 12-month post index date 
N=954,022 
Age ≥ 18 years old 
 
N=953,364 
At least 395 days EMR activity prior to the index date 
 
N=557,957 
At least 30-month EMR activity post index date 
 
N=297,394 
No major cardiovascular disease or major cerebrovascular disease, 







No hepatic dysfunction or rhabdomyolysis, 
prior to the index date 
N=142,246 
One LDL-C reading within 6-month prior to the index date 
 
N=82,084 
One LDL-C reading within 0-12 month post index date 
 
N=56,534 





































This study of 52,126 patients in a nationwide EMR database between 1996 - 2010,  
 
found a significant association between the risk of CV events and LDL-C goal attainment.  
 
Notably, the study found that the likelihood of a CV event due to patients failing to attain  
 
or maintain LDL-C goal at any time during the follow-up period was 2.6 times compared  
 
to those achieving goals. The other factors with a significant association with CVD risk  
 
from highest to lowest in strength were ATP III risk group, age, hypertension, race, and  
 




This study contributes to the literature by evaluating the real-world effects of  
 
LDL-C levels on CVD risks per risk-based targets in patients treated with a statin. The  
 
increase in CVD risk with goal attainment failure accentuated the importance of  
 
consistency in maintaining LDL-C goal status and suggested that LDL-C reduction  
 
should be the life-long primary target of cholesterol therapy for patient’s identified at  
 
high risk for CVD [4]. Recently, the American College of Cardiology and American  
 
Heart Association together with the National Heart, Lung, and Blood Institute published  
 
new guidelines, which focus on risk-based treatment intensity versus specific LDL-C  
 
targets. The results presented here serve as evidence that while guidelines may now be  
 




appropriate intensity per CV-risk remains relevant in primary prevention of CV events.  
 
Since ATP III, we have seen rises in prescriptions of statins in primary prevention [40].  
 
However, as observed in this study, more than half (60%-85%) of the patients failed to  
 
maintain the LDL-C goal for at least 10% of the follow-up period, meaning that  
 
prescribing statins does not alone guarantee stable and consistent reduction in LDL-C  
 
levels. In addition to prescribing appropriate doses and statin potency, patient adherence  
 
to the long-term pharmacotherapy and non-adherence is also key to LDL-C goal  
 
attainment. Therefore, increasing in the overall utilization of statins does not assure an  
 
improvement in primary prevention outcomes across a population, and more systematic  
 
efforts in medication adherence improvement, disease, and wellness education should  
 
also be undertaken. These efforts could come as a collaboration of healthcare providers  
 
and payers, and studies have found that such patient-centered care management programs  
 
improve both clinical and economic outcomes [33]. 
 
The target population who were prescribed statins for primary prevention has  
 
been estimated in the tens of millions in the United States. A strength of this study is that  
 
it evaluates LDL-C reduction after statin therapy in a real-world setting using data from a  
 
large, national EMR database. With these data, the findings were not limited to a specific  
 
region or insurance type, and patients were not excluded due to poor control of comorbid  
 
conditions. Thus, this observational study demonstrates the effectiveness in the  
 




Prevalence of diagnosed baseline hypertension (52.9%) in this study was low,  
 





of hypertension in the EMR as the percentage of patients commonly treated with  
 
antihypertensive medications was considerably higher (74.9%). While the reason for use  
 
of antihypertensive medications was not captured, this treatment rate is more consistent  
 
with what would be expected in this cohort [36].  
 
In the early phase of this research, another stratifying algorithm which grouped  
 
patients by their first-goal-failure time (early failure/late failure/no failure) was used. This  
 
approach led to the realization that a first-goal-failure was not sensitive enough in  
 
classifying the exposure to elevated LDL-C. Thus, a time-dependent approach was  
 
adopted for this project.  
 
This study contributes to quantification of time-variant LDL-C goal attainment  
 
and risk of CVD in a real-world setting, but it comes with several limitations. First, while  
 
a large national dataset, it is not nationally representative, and the population is skewed to  
 
patients with health insurance, and who are younger, non-African Americans. Second, the  
 
study includes patients with a minimum follow-up period and monitored by their provider  
 
more consistently, which might lead to better health outcomes. Finally, data for several  
 
factors that can influence CVD risk, including reliable smoking and alcohol consumption  
 
data, as well as diet and exercise information, are not captured in this EMR database.  
 
Further, pharmacy dispensing data are not available in EMR datasets, which limited our  
 
ability to control for medication adherence as a potential confounder. If a prescription  
 
order for a drug was not captured from the database or it was not in the medication list, it  
 
was assumed that there was no treatment, which could cause potential misclassification.  
 
Also, if baseline characteristics such as race, region, and insurance type were not reported,  
 





these characteristics. However, other than race, which is ubiquitously underreported in  
 
secondary datasets, missing data generally accounted for a small proportion of records of  
 
data obtained from the EMR database.  
 
In conclusion, this study found that failure to attain LDL-C goal at any time  
 
during the follow-up period increased the likelihood of CV event occurrence. Future  
 
studies, such as evaluation of real-world treatment outcomes under the new ACC/AHA 
 
guidelines, or a study that controls for adherence to isolate if failure to attain or maintain  
 










Codes for Identifying Antihyperlipidemics Medications 
 
GPI subclass for Index Date Prescription (Statins) Generic name 
HMG COA Reductase Inhibitors Atorvastatin Calcium 
HMG COA Reductase Inhibitors Fluvastatin Sodium 
HMG COA Reductase Inhibitors Lovastatin 
HMG COA Reductase Inhibitors Pravastatin Sodium 
HMG COA Reductase Inhibitors Rosuvastatin Calcium 
HMG COA Reductase Inhibitors Simvastatin 








Diagnoses Codes Description 
Ischemic Heart Disease (MI) 410.x Acute myocardial infarction 
411.x Other acute and subacute forms of ischemic heart disease 
412.x Old myocardial infarction 
Ischemic Heart Disease (Angina) 413.x Angina pectoris 
Ischemic Heart Disease (Other forms) 414.x Other forms of chronic ischemic heart disease 
Cerebrovascular Disease 430.x Subarachnoid hemorrhage 
431.x Intracerebral hemorrhage 
432.x Other and unspecified intracranial hemorrhage 
433.x Occlusion and stenosis of precerebral arteries without infarct 
434.x Occlusion of cerebral arteries without infarct 
436.x Acute, but ill-defined, cerebrovascular disease 
437.x Other and ill-defined cerebrovascular disease 
438.x Late effects of cerebrovascular disease 
Peripheral Vascular Disease 443.x Other peripheral vascular disease 
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Table 6 continued 
 
Diagnoses Codes Description 
Non-coronary forms of atherosclerotic 
disease (Abdominal aortic aneurysm) 
441.3x Abdominal aneurysm ruptured 
441.4x Abdominal aneurysm without rupture 
Diagnoses Codes Description 
Non-coronary forms of atherosclerotic 
disease (Abdominal aortic aneurysm) 
442.x Other aneurysm 
Non-coronary forms of atherosclerotic 
disease (Carotid artery disease) 
433.1x Occlusion and stenosis of carotid artery 
Hypertension 401.xx Essential hypertension 
 402.xx Hypertensive heart disease 
 404.xx Hypertensive heart and kidney disease 
 405.x Secondary hypertension 







Codes for Identifying Antihyperlipidemics Medications 
 
GPI subclass for Post Index Date Prescription Generic name 
Non-Statins  
Antihyperlipidemics - misc. Omega-3-acid ethyl esters 
 Policosanol 
Bile Acid Sequestrants Cholestyramine 
 Cholestyramine Light 
 Colesevelam HCL 
 Colestipol HCL 
Fibric Acid Derivatives Choline Fenofibrate 
 Fenofibrate 
 Fenofibrate Micronized 
 Fenofibric Acid 
 Gemfibrozil 
Intestinal Cholesterol Absorption Inhibitors Ezetimibe 
Nicotinic Acid Derivatives Niacin 




Table 7 continued 
 
GPI subclass for Post Index Date Prescription Generic name 
HMG COA Reductase Inhibitors Niacin-Lovastatin 
 Aspirin Buffered-Pravastatin 




APPENDIX B  
 
 






The MEGA study initiated 10-20mg/d pravastatin to patients aged 40-70 years old,  
 
who met the inclusion criteria: TC 220-270 mg/dL, bodyweight > 40 kg[10]. A total of  
 
7,832 patients were enrolled and followed up for a mean of 5.3 years. A total of 3,866  
 
patients were enrolled in the case arm and 3,966 in the control arm. In the pravastatin  
 
group, 95% patients were appliance with medication at year 1, 90% at year 5, and 89% at  
 
year 9. Primary endpoint was CVD which included MI (HR=0.67, 95% CI [0.49, 0.91],  
 
P=0.01), sudden cardiac death (HR=0.51, 95% CI [0.18, 1.50], P=0.21), angina  
 
(HR=0.83, 95% CI [0.56, 1.23], P=0.35), coronary revascularization (HR=0.60, 95% CI  
 
[0.41, 0.89], P=0.01).  Significant reductions in TC, LDL-C were noted in the case arm  
 
compared with the control arm. TC decreased by 12% in the pravastatin group at year 5  
 
compared with 3% in the placebo group; LDL: -19% vs. -5%; TG: -13% vs. -10%; HDL:  
 
7% vs. 5%. This study showed that low doses of pravastatin can reduce the risk of MI,  
 
with small to moderate reductions in TC and LDL-C concentration. This study also  
 
showed no statistically significant difference in sudden cardiac death, angina, as well as  
 





ASPEN enrolled patients aged 40-75 years old, who had type 2 diabetes, and met  
 
serum lipid inclusion criteria[7]. Exclusion criteria included type 1 diabetes; myocardial  
 
infarction, interventional procedure, or episodes of unstable angina ≤3 months before  
 
screening; HbA1C >10%; active liver disease or hepatic dysfunction; severe renal  
 
dysfunction or nephrotic syndrome; congestive heart failure treated with digoxin; creatine  
 




kg/m2; abuse of alcohol and/or drugs; and placebo run-in compliance rate <80%. There  
 
were 959 patients recruited in the atorvastatin group, and 946 in the placebo group. After  
 
a 4-year follow-up, 100 patients developed primary composite endpoint events (MI,  
 
stroke, sudden cardiac death, heart failure, arrhythmic non-sudden CV death,  
 
recanalization, coronary artery bypass grafting, resuscitated cardiac arrest, worsening or  
 
unstable angina hospitalization) in the case arm, and 102 in the control arm, with hazard  
 
ratio of 0.9 (95% CI [0.73, 1.12], P=0.341). As for the secondary endpoint all-cause  
 
mortality, there were 44 events out of 959 in the case arm compared with 41 events out of  
 
946 in the control arm, with a hazard ratio of 1.06 (95% CI [0.69, 1.62], P>0.05). The  
 
results indicated that no statistically significant difference lied between atorvastatin and  
 
placebo groups in terms of composite endpoint as well as all-cause mortality. Significant  
 
mean percent reductions from baseline were observed for LDL-C, TC, and TG in the  
 





The results of JUPITER were so far the most promising on primary prevention in  
 
statin therapy[41]. The study enrolled 17,802 people with LDL-C less than 130 mg/dL  
 
and high-sensitivity C-reactive protein (hsCRP) larger than 2.0 mg/L, and issued 20 mg  
 
daily rosuvastatin to patients randomly selected in control group. Exclusion criteria were:  
 
current use of statin or other lipid-lowering therapies, including fibrates, niacin, and bile- 
 
acid sequestrants; known hypersensitivity to statin therapy; current use of  
 
postmenopausal oral hormone therapy; current use of immune-suppressants; active liver  
 
disease or elevated liver enzymes; creatine kinase [CK] >3 times ULN; diabetes mellitus  
 




uncontrolled hypertension (systolic or diastolic blood pressure >190 or 100 mm Hg,  
 
respectively); history of cancer, except non-malignant skin cancer, within the past 5 years;  
 
uncontrolled hypothyroidism; chronic inflammatory conditions such as severe arthritis,  
 
lupus, or inflammatory bowel disease; history of alcohol or drug abuse within the past  
 
year; and serious medical or psychological conditions that may compromise successful  
 
study participation. Terminated over a median of 1.9 years of follow-up, which was  
 
previously scheduled around 5 years, JUPITER found a 46.8% and 45.8% decrease in  
 
LDL for women and men, respectively, and 20% all-cause mortality reduction. The  
 
primary endpoint, which was a combined outcome of MI, stroke, arterial  
 
revascularization, hospitalization for unstable angina, or death from CV events, showed a  
 
hazard ratio of 0.56 (95% CI [0.46, 0.69], P<0.001). The secondary endpoint which was  
 




However, the efficacy and effectiveness of JUPITER was criticized immediately  
 
after  the results were released. Yusuf et al. pointed out that JUPITER Independent Data  
 
and Safety Monitoring Board (IDSMB) terminated the trial after 1.9 years median  
 
follow-up which exaggerated its findings since given a longer follow-up time, the early  
 
effects of the benefits seen in JUPITER would diminish [42]. After re-examining the  
 
clinical outcomes in JUPITER, de Lorgeril et al. found cardiovascular mortality (fatal  
 
stroke plus fatal MI) to be identical between the control and placebo groups (12 vs.  
 
12)[43]. Therefore, they concluded that “JUPITER dataset appears biased” and “should  
 
have led to the continuation of the trial rather than to its premature ending”. Kaul et al.  
 





which compared 91 truncated with 424 matched nontruncated RCTs, and found the  
 
pooled ratio of relative risks as 0.71(95% CI [0.65, 0.77]) suggesting that early truncation  
 
of clinical trials could be premature[44]. Kaul also cited two other trials for supporting  
 
the idea that early benefits seen in truncated trials would disappear later on final  
 





In CARDS, there were overall 2,838 patients aged 40–75 years old, randomized  
 
to atorvastatin 10 mg daily (n=1428) or placebo (n=1410)[8]. Patient inclusion criteria  
 
were no documented previous history of cardiovascular disease, LDL-C≤160.07 mg/dL,  
 
fasting TG≤603 mg/dL, and at least one of the following: type 2 diabetes, retinopathy,  
 
albuminuria, current smoking, or hypertension. The primary endpoint was time to first  
 
occurrence of the following: acute coronary heart disease events, coronary  
 
revascularization, or stroke. Since the early stopping rule for efficacy was met, the trial  
 
was terminated 2 years earlier. With a median follow-up of 3.9 years, the relative  
 
reduction rate for at least one major CV event was 0.63 (95% CI [0.48, 0.83], p=0.001),  
 
and for stroke was 0.52 (95% CI [0.31, 0.89], p=0.001). There was a 40% decrease in  
 
LDL-C level, 26% decrease in HDL-cholesterol level, 19% decrease in TG level, and 1%  
 
increase in TC level with p-value all less than 0.01.  However, there was no statistically  
 





A total of 6,605 patients with average TC and LDL-C and below-average HDL-C  
 





hyperlipidemia, type 1 or 2 diabetes. After an average follow-up of 5.2 years, lovastatin  
 
reduced the incidence of major coronary events (HR=0.63, 95% CI [0.50, 0.79], P<0.001),  
 
MI (HR=0.6, 95% CI [0.43, 0.83], P=0.002), unstable angina (HR=0.68; 95% CI [0.49,  
 
0.95], P=0.02), coronary revascularization procedures (HR=0.67, 95% CI [0.52, 0.85],  
 
P=0.001), coronary events (HR=0.75, 95% CI [0.61, 0.92, P=0.006), and cardiovascular  
 
events (HR=0.75, 95% CI [0.62, 0.91], P=0.003). Lovastatin (20-40 mg daily) reduced  
 
LDL-C by 25% to 115 mg/dL and increased HDL-C by 6% to 39 mg/dL. There were  
 
totally 80 deaths in case cohort and 77 deaths in control cohort, with hazard ratio of 1.04  
 
(95% CI [0.76, 1.42], P>0.05). AFCAPS did not reveal a trend of difference in mortality  
 
between case and control arms either. 
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Relative Risk for ATP III Risk Factors Defined by ATP III 
 
 Men Women 
 Relative Risk 95% CI P-value Relative Risk 95% CI P-value 
Age (y) 1.05 1.04,1.06 <0.001 1.04 1.03,1.06 <0.001 
Blood Pressure  
Normal 1.00   1.00   
Stage I 1,73 1.32,2.26 <0.001 1.34 0.88,2.05  
Stage II 1.92 1.42, 2.59 <0.001 2.19 1.46, 3.27 <0.001 
Cigarette use (y/n) 1.71 1.39-2.10 <0.001 1.49 1.13-1.97 <0.01 
LDL-C, mg/dL  
<130 1.00   1.00   
130-159 1.19 0.91-1.54 0.05 1.24 0.84-1.81 0.05 
≥160 1.74 1.36-2.24 <0.001 1.68 1.17-2.40 <0.01 
HDL-C, mg/dL  
<35 1.46 1.15-1.85 <0.01 2.08 1.33-3.25 <0.01 
35-39 1.00   1.00   






LDL-C Goals in Different Risk Categories 
 
Risk Category  LDL Goal 
LDL Level at Which to 
Initiate TLC 
LDL Level at Which to 
Consider Drug Therapy 
CVD or CVD Risk 
Equivalents* 
<100 mg/dL ≥100 mg/dL ≥130 mg/dL 
2+ ATP III Risk 
Factors 
<130 mg/dL ≥130 mg/dL 
≥130 mg/dL or ≥160 
mg/dL† 
0-1 ATP III Risk 
Factor 
<160 mg/dL ≥160 mg/dL ≥190 mg/dL 
____________________ 
* CVD risk equivalents include: other clinical forms of atherosclerotic disease 
(Peripheral arterial disease, abdominal aortic aneurysm, and carotid artery disease), 
diabetes, and multiple risk factors.  Source: ATP III report, Circulation, July 13, 2004. 
 
† Depends on 10-year risk based on Framingham Study, electronic 10-year risk 
















Kyoichi et al, 
2006 
MEGA 7,832 Pravastatin Diet 5.3 Indication of secondary prevention >89% 
Knopp et al, 
2006 
ASPEN 1,905 Atorvastatin Placebo 4.3 BP>160/100, BMI>35, run-in compliance rate <80% >80% 
Mora et al,  
2010 
JUPITER 17,802 Rosuvastatin Placebo 1.9 Type 2 diabetes, BP>190/100 >80% 
Helen et al,  
2004 
CARDS 2,838 Atorvastatin Placebo 4.0 Indication of secondary prevention >80% 
Downs et al, 
1998 
AFCAPS 6,605 Lovastatin Placebo 5.2 
Type 2 diabetes, weight more than 50% greater than the 





RCTs Results for Statin Effect on Cholesterol Lowering 
Trials Baseline At 12 months Change Change Percentage 
JUPITER Rosuvastatin Placebo Rosuvastatin Placebo Rosuvastatin Placebo Rosuvastatin Placebo 
LDL 108.0 108.0 55.0 110.0 -51.0 4.0 -47.2% 3.7% 
HDL 49.0 49.0 52.0 50.0 3.0 1.0 6.1% 2.0% 
TG 118.0 118.0 99.0 119.0 -17.0 -1.0 -14.4% -0.9% 
MEGA Pravastatin Diet Pravastatin Diet Pravastatin Diet Pravastatin Diet 
LDL 156.6 156.6 127.6 153.5 -29 -3.1 -18.5% -2.0% 
HDL 57.6 57.6 60.3 58.4 2.7 0.8 4.7% 1.4% 
TG 128.2 128.2 109.9 117.8 -18.3 -10.4 -14.3% -8.1% 
TC 242.4 242.4 213.4 239.3 -29.0 -3.1 -12.0% -1.3% 
ASPEN* Atorvastatin Placebo Atorvastatin Placebo Atorvastatin Placebo Atorvastatin Placebo 
LDL 114 114 79.3 113.5 -34.8 -0.6 -30.5% -0.5% 
HDL 48 47 48.9 46.8 0.9 -0.2 1.9% -0.3% 
TG 145 144.5 138.2 155.0 -6.8 10.5 -4.7% 7.2% 
TC 195 195 156.4 192.3 -38.6 -2.7 -19.8% -1.4% 
  
62 
Table 11 continued 
Trials Baseline At 12 months Change Change Percentage 
AFCAPS Lovastatin Placebo Lovastatin Placebo Lovastatin Placebo Lovastatin Placebo 
LDL 92.0 158.4 115 156 -23.0 2.4 -25.0% 1.5% 
HDL 41.5 38.5 39 38 2.5 0.5 6.0% 1.2% 
TG 124.3 159.3 143 163 -18.7 -3.7 -15.0% -2.3% 
TC 155.4 230.1 184 228 -28.6 2.1 -18.4% 0.9% 
CARDS Atorvastatin Placebo Atorvastatin Placebo Atorvastatin Placebo Atorvastatin Placebo 
LDL 117.5 116.8 71.9 119.9 -45.6 3.1 -38.8% 2.7% 
HDL 53.7 54.9 53.0 53.0 -0.7 -1.9 -1.3% -3.5% 
TG 173.6 171.8 143.3 169.1 -33.0 2.6 -19.0% 1.5% 
TC 207.2 206.9 159.3 204.2 -53.7 2.7 -25.9% 1.3% 
____________________ 





Primary Prevention RCTs Results on Primary Endpoint 
 
Title 
Events for Primary Endpoint 
Hazard Ratio 95% CI P-value 
Statin  Placebo 
MEGA 66 101 0.67 0.49 0.91 0.01 
ASPEN 100 102 0.90 0.73 1.12 0.34 
JUPITER 142 251 0.56 0.46 0.69 <0.001 
CARDS 83 127 0.63 0.48 0.83 0.001 






Number of Events and Incidence Rate of CV Events by ATP III Risk Factor 
 
ATP III Risk 
FactorEvent/Rate* 
MI Anigna Cerebrovascular Composite 
0~1 
55 60 259 374 
0.109 0.119 0.510 0.734 
2+ 
110 97 528 735 
0.260 0.229 1.237 1.713 
CVD/CVD Equivalent 
259 150 503 912 
0.833 0.482 1.604 2.892 
Total 
424 307 1,290 2,021 
0.342 0.248 1.033 1.61 
____________________ 
































0.70 <0.05 NA NA 0.94 >0.05 0.71 <0.05 
Choudhry et 
al 
0.71 <0.05 0.86 0.02 0.92 >0.05 0.77 <0.05 
Brugts et al 0.70 <0.05 0.81 <0.05 0.88 <0.05 0.88 >0.05 
Ray et al NA NA NA NA 0.91 >0.05 NA NA 
Cochrane 
Review 






Summary of Studies on Suboptimal Use of Statin and Reduction of CV Events 
 
Title Population Comparator Follow-up1 End points 
Risk Reduction 
Rate2 95% CI 
Perreault et al, 2007 20,543 
PDC3 
≥90% vs. <90% 
1.6 years Non-fatal coronary artery disease event4 0.81 0.67, 0.97 
Perreault et al, 2009 115,290 
MPR5 
≥80% vs. <20% 
6 months- 
6.5 years 
Coronary artery disease event6 0.82 0.77, 0.87 
Perreault et al, 2009 112,092 
MPR 
≥80% vs. <20% 
2.95 years Cerebrovascular disease7 0.74 0.65, 0.84 
____________________ 
1 Mean follow-up was reported here.  
 
2 Risk reduction was compared between case and control after one-year statin therapy treatment. 
 
3 Proportion of Days Covered, defined as the number of days medication was supplied divided by the observation time interval. 
 
4 Non-fatal coronary artery disease was defined as a composite end-point of nonfatal myocardial infarction or angina; a 
revascularization procedure, angioplasty, coronary artery bypass graft; or initiation of treatment with a nitrate drug. 
 
5 Medication Possession Ratio, defined as number of day’s supply of medication filled divided by the length of follow-up (from the 
beginning of first fill through the end of last fill). 
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